Protocol v1 - conduit4olt.org Outcome Analysis of Arterial Conduits in Liver Transplantation

BACKGROUND

Arterial conduits in liver transplantation are almost as old as the procedure itself. First described by Starzl in 1984, the knowledge remains superficial. Although rarely performed, there is no doubt that thousands of patients' lives were saved because of the use of arterial grafts. However, arterial grafts are known to be associated with a **higher rate of occlusion** and a **lower patient and graft survival** when compared to conventional end-to-end anastomosis. In our recent retrospective study, we showed that retransplantation procedure and aspirin in patients' medication are independent risk factors for the need of an aorto-hepatic conduit. We assume that aspirin could be a surrogate marker for vascular and metabolic status. Furthermore, in our meta-analysis we found a four times higher occlusion rate compared to nonconduits.

Whether the site of conduit placement (Figure 1) or certain types of material have an impact on occlusion and graft survival remains unknown. In addition, several studies discuss that antiaggregation or anticoagulation might be protective for occlusion of arterial conduits. Currently, there is no study that investigated this problem, most probably because of low case numbers.




Figure 1

STUDY OBJECTIVES

The primary goal of this study is to conduct a multicenter cohort analysis to define the **outcome of different types of conduits and to investigate whether antiplatelet / anticoagulation has an impact on patency rates.**

Specific aim #1: To identify independent risk factors for early and late occlusion of arterial conduits in liver transplantation.

Specific aim #2: To compare different placement sites (infrarenal, supraceliac, lliacal, etc) of arterial conduits (<u>Figure 1</u>) in terms of occlusion rates and graft survival.

Specific aim #3: To investigate whether antiagregation therapy is protective in terms of arterial patency.

STUDY DESIGN

This will be a multicenter single cohort study including only cases of deceased donor liver transplantation that required an aorto-hepatic or iliac-hepatic conduit for arterial reconstruction. Primary endpoint is 30-day conduit patency. Secondary endpoints include postoperative complications, death, late conduit occlusion, graft and patient survival.

The study protocol has received approval by the local ethics committee and will be soon registered at ClinicalTrials.gov, as well as published here prior to data collection.

SETTING

This multicenter cohort study will include several high -volume centers worldwide. Each participating center requires a prospective database from that data can be extracted. All consecutive cases of deceased donor liver transplantation requiring an aorto-hepatic conduit *from 1st of January 2007 until 31st of December 2016* are included allowing a minimum follow-up time of 6 months. Data collection at conduit4olt.org will be prospective, structured, anonymized, and encrypted.

2

PUBLICATION POLICY

For upcoming publications, two authorships of the participating centers will be guaranteed as a group-authorship indexed in PubMed.

INSTITUTIONAL REVWIEW BOARD (IRB) / ETHICAL POLICY

Each participating center is responsible to contact their local ethics committee and receive approval for participation, if applicable. For example, this project is considered as an audit in some countries and thus there is no need for formal approval in the form of a protocol submission.

ELIGIBILITY CRITERIA

Inclusion criteria:

- Liver transplantation requiring aorto-hepatic or iliac-hepatic conduits
- Deceased donor after brain death (DBD) or deceased donor after circulatory death (DCD)
- Whole organ as well as split allografts
- Primary liver transplantation as well as liver retransplantation
- Adult recipient (age ≥18 years)

Exclusion criteria:

- Living donor liver transplantation
- Pediatric liver transplantation (recipient age <18 years)
- Arterial reconstruction other than aorto-hepatic or iliac-hepatic conduits
- Multivisceral transplantations

VARIABLES

The PDF version of the online Case Report Form is available at the Appendix.


ESTIMATED SAMPLE SIZE

Each center should provide at least 30 cases that meet the inclusion criteria to allow adequate event rates for each outcome.

STATISTICAL METHODS

The primary and secondary endpoints will be compared with patient and operation characteristics with univariate analysis. ROC Curve analysis will be performed to dichotomize continuous variables. Multivariable analysis (binary logistic and Cox regression) will be performed to identify independent risk factors. Statistical analysis will be performed using R Studio version 1.0.44 (RStudio, Inc. GNU Affero General Public License v3, Boston, MA, 2016) with the graphical user interface rBiostatistics.com beta version (rBiostatistics.com, Zurich, Switzerland, 2016, GNU License).

Christian E. Oberkofler, Tim Reese, Dimitri A. Raptis, and Henrik Petrowsky On behalf of the conduit4olt.org team Swiss HPB Center, Department of Surgery and Transplantation, University Hospital Zurich, Switzerland conduit4olt.org




ife support prior to transplantation *					
		Ye	s N	0	Unknown
Dialysis prior to transplantation		C			0
Ventilation prior to transplantation					0
Vasopressors prior to transplantation					0
Retransplantation * O Yes O No Retransplantation indicates prior liver transpl		-			
Underlying liver disease (multiple option	ons): *				
	Y	es	No		Unknown
Non-alcoholic steatohepatitis	(\supset	0		0
Hepatitis B virus infection	(0	0		\bigcirc
Hepatitis C virus infection	(0	0		0
Alcohol	(С	0		0
Autoimmune hepatitis	(С	0		0
Wilson's disease	(С	0		0
Other	(С	0		0
f other underlying liver disease, pleas	e indicate				
ndication for transplantation (multiple	options): *			1	
	Yes	S	No		Unknown
Acute liver failure	0		\bigcirc		\bigcirc
Hepatocellular carcinoma	0		\bigcirc		0
Cholangiocarcinoma	0		\bigcirc		0
		-			

Other	0	0	\bigcirc
other indication for liver transplantat	ion, please ind	icate	
ACE prior to transplantation O Ye			
adiation prior to transplantation) Yes 🔵 No carcinoma.		
omorbidities *	No	N	
	Yes	No	Unknown
Coronary artery disease	0	0	0
Stroke prior to transplant	0	0	0
Smoker	0	0	0
Valvular heart disease	0	0	0
Heart arrhythmias	0	0	0
Hypertension	0	0	0
Cerebrovascular disease	0	0	0
Hypercoagulation disease	0	0	0
Dyslipidemia	0	0	0
Diabetes mellitus	0	0	0
Stroke	0	0	0
Smoker	0	0	0
Sepsis / septic shock	0	0	0
Other	0	0	0

If other comorbidities, please indicate

	Yes	No	Unknown
	res	NO	Unknown
Antiplatelet agents	0	0	0
Anticoagulant agents	0	0	0
If yes, please indicate which m	edications:		
Dabigatran (Pradaxa), Apixaban (El Fondaparinux (Arixtra), etc.	iquis), Edoxaban (S	Savaysa), Enoxa	aparin (Lovenox),
Operation characteristics			
Graft type * 🔿 DBD 🔿 D	CD		
DBD indicates donor after brain dea	th. DCD indicates of	lonor after card	ac death
Simultaneous kidney transplar	ntation * 🔵 Ye	s 🔿 No	
Cold ischemia time *	minutes		
Operation duration *	minutes		
Use of veno-venous bypass *	O Yes O M	No	
Operation technique * O Cl	assic 🔵 Pigg	y-bag	
	es *		
Number of arterial anastomose		04 05	
Number of arterial anastomose	0203	\sim \sim	
	0203	0	
	0203	0	



Reason for need of conduit * - Select - +			
If other reason for need of conduit, please indicat	е		
Additional arterial back-table reconstructions? *	O Yes	O No	1
Biliary reconstruction * - Select -			
Intraoperative blood product administration *			
	Yes	No	Unknown
Intraoperative fresh-frozen Plasma (FFP)	0	0	0
Intraoperative red blood cells (RBC)	0	0	0
Intraoperative platelets (Plt)	0	0	0
If FFP, how many units?			
If RBC, how many units?			
If Plt, how many units?			

Medications post transplantation Immunosuppression post transplantation Immunosuppression post transplantation (multiple options) * Azathioprine Corticosteroids Cyclosporine Everolimus Mycophenolate Sirolimus Other None

Anticoagulation post transplantation	(multiple op	otions): *	
	Yes	No	Unknown
Antiplatelet agents	0	0	0
Anticoagulant agents	0	0	0
		tiooogulant	agonto:
f yes, please indicate which medica E.g. Antiplatelet agents: Aspirin, Clopidogr Phenprocoumon (Marcoumar), Warfarin (C Heparin (Liquemin), Dabigatran (Pradaxa) Enoxaparin (Lovenox), Fondaparinux (Arix f anticoagulation, please indicate ta Therapeutic Prophylactic therapy means 10000 or 1500	el (Plavix). An coumadin), Riv Apixaban (El tra), etc. rget therapy	varoxaban (X iquis), Edox v O Pro	Xarelto), Heparin, aban (Savaysa), phylactic

Posttransplantation outcome
Lab values
Peak AST (up to 7th post-TPL day) *
Peak ALT (up to 7th post-TPL day) *
Bilirubin at 7th post-TPL day * μ mol/l (SI)
Typical normal ranges 3-25 (μ mol/l) (SI)
INR at 7th post-TPL day * ratio
Typical normal ranges 3-25 (µmol/l) (SI)

Lab unit converter

Clavien-Dindo Classification of Postoperative Complications within 90 days post-TPL *

	None	1	2	3a	3b	4a	4b	5 (death)
Biliary	0	0	0	0	0	0	0	0
Bleeding	0	0	0	0	0	0	0	0
Graft related	0	0	0	0	0	0	0	0
Hemodynamic	0	0	0	0	0	0	0	0
Infections	0	0	0	0	0	0	0	0
Neurologic	0	0	0	0	0	0	0	0
Renal	0	0	0	0	0	0	0	0
Respiratory	0	0	0	0	0	0	0	0
Vascular	0	0	0	0	0	0	0	0
Other A	0	0	0	0	0	0	0	0
Other B	0	0	0	0	0	0	0	0
Other C	0	0	0	0	0	0	0	0

Please indicate all different types of complications and their grades according to the Clavien-Dindo Classification from transplantation until the 90th posttransplantation day. If the recipient did not encounter any complications from operation until discharge, please indicate "None" for all types and grades of complications.

- None -

- None -

- None -

÷)

ŧ

÷)

If biliary complication, indicate type

If vascular complication, indicate type

If graft related complication, indicate type

If there were any other types of complications encountered, please describe them

below:
<i>h</i>
Clavien-Dindo Classification
Length of ICU stay * days
In case of readmission(s) to the Intensive Care Unit (ICU), please indicate the total number of ICU stay in days above.
Length of hospital stay * days
Readmission within 90 days from transplantation * 🔵 Yes 🔵 No
If yes, what was the reason for readmission?

Arterial patency from transplantation until last follow up or death
Occlusion indicates total occlusion while stenosis indicates partial occlusion.
Arterial occlusion / stenosis - First occasion
Occlusion indicates total occlusion while stenosis indicates partial occlusion.
Arterial occlusion / stenosis * - Select - +
If yes, days from transplantation to arterial occlusion / stenosis
days
If stenosis (partial occlusion), please indicate the reason
- None - 🔶
First Intervention type (multiple options):
Percutaneous transluminal angioplasty (PTA)
C Stent
Thrombolytic therapy
Redo of the anastomosis
Redo of the conduit
Other

es indicates that after the intervention, the artery remained opened, thus rescues the intervention. No means that the intervention was unsuccessful.	d by the
econd occasion - Arterial reocclusion / restenosis	
Dcclusion indicates total occlusion while stenosis indicates partial oc	clusion
	01001011
arterial reocclusion / restenosis *	
yes, days from first occlusion to reocclusion	
ays	
occlusion contains also clinically relevant stenosis (i.e. partial occlusion)	
restenosis (partial occlusion), please indicate the reason	
- None - 🔶	
Reintervention type (multiple options):	
Percutaneous transluminal angioplasty (PTA)	
Stent	
Thrombolytic therapy	
Redo of the anastomosis Redo of the conduit	
Other	
yes, patency rescue by reintervention O Yes O No es indicates that after the intervention, the artery remained opened, thus rescuentervention. No means that the intervention was unsuccessful.	d by the
hird occasion - Arterial re-reocclusion / re-restenosis	
Declusion indicates total occlusion while stenosis indicates partial oc	clusion
arterial re-reocclusion / re-restenosis * - Select -	
yes, days from reocclusion to re-reocclusion	
ays occlusion contains also clinically relevant stenosis (i.e. partial occlusion). This du ays indicates the time from second to third occlusion.	ration in
re-restenosis (partial occlusion), please indicate the reason	

Re-reintervention type (mu	ultiple options):
Percutaneous translum	ninal angioplasty (PTA)
Stent	
Thrombolytic therapy	
Redo of the anastomos	sis
Redo of the conduit	
Other	
	re-reintervention O Yes O No ervention, the artery remained opened, thus rescued by the e intervention was unsuccessful.
Survival Patient status *	O Dead
ollowed up at the outpatient clinic Below you are requested to indice or death.	ther the patient was last seen alive or dead at the hospital, c, family doctor, or confirmed after being contacted by phone. ate the number of days from transplantation until last follow up
Days from transplantation to	
	days
	death or last follow up recording. This value (number of days) plantation to the last follow up recording for alive patients or the h for those that died.
Graft status * 🔵 Graft fur	nctioning 🔘 Graft failure
Graft failure indicates retransplan	itation or patient death.
Days from transplantation to	b last follow up or graft failure *
	days
-	ated from the date of transplantation to the date of graft was functioning at the last follow up, please indicate the st follow up.

1,

Submit

Platforn	n
----------	---

Home

About

Team

Data Entry

Protocol Instructions Submit cases

Contact us

Prof Henrik Petrowsky Dr Christian Oberkofler Dr Dimitri Raptis

Headquarters

University Hospital Zurich Rämistrasse 100 8091 Zurich, Switzerland

© 2017 conduit4OLT.org. All Rights Reserved.

Design by Dimitri Raptis